About Antisense and RNAi Therapeutics
Antisense and RNAi therapeutics are novel therapeutic options with potential to treat diseases such as chronic liver and cardiovascular diseases, Huntington disease, and even rare diseases.
Analysts forecast the Global Antisense and RNAi Therapeutics Market to grow at a CAGR of 8.67% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the antisense and RNAi therapeutics market. To calculate the market size, the report considers the revenue generated from the application of antisense and RNAi therapeutics across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Report, antisense and RNAi therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Alnylam Pharmaceuticals
• Bausch Health
• Biogen
• Sarepta Therapeutics
Market driver
• High target affinity and specificity of RNAi therapeutics
• For a full, detailed list, view our report

Market challenge
• High price of RNAi drugs
• For a full, detailed list, view our report

Market trend
• Growing potential to address multiple therapy areas
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.